EP3855186A2 - Verfahren zur bestimmung der wirksamkeit eines impfstoffs - Google Patents

Verfahren zur bestimmung der wirksamkeit eines impfstoffs Download PDF

Info

Publication number
EP3855186A2
EP3855186A2 EP21173934.7A EP21173934A EP3855186A2 EP 3855186 A2 EP3855186 A2 EP 3855186A2 EP 21173934 A EP21173934 A EP 21173934A EP 3855186 A2 EP3855186 A2 EP 3855186A2
Authority
EP
European Patent Office
Prior art keywords
seq
antibody
antibodies
subject
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP21173934.7A
Other languages
English (en)
French (fr)
Other versions
EP3855186B1 (de
EP3855186C0 (de
EP3855186A3 (de
Inventor
designation of the inventor has not yet been filed The
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euroimmun Medizinische Labordiagnostika AG
Original Assignee
Euroimmun Medizinische Labordiagnostika AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euroimmun Medizinische Labordiagnostika AG filed Critical Euroimmun Medizinische Labordiagnostika AG
Priority to DE21173934.7T priority Critical patent/DE21173934T1/de
Publication of EP3855186A2 publication Critical patent/EP3855186A2/de
Publication of EP3855186A3 publication Critical patent/EP3855186A3/de
Application granted granted Critical
Publication of EP3855186B1 publication Critical patent/EP3855186B1/de
Publication of EP3855186C0 publication Critical patent/EP3855186C0/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Definitions

  • the invention relates to a method for determining the immune status of a subject, more specifically whether the subject has been vaccinated with a composition comprising SEQ ID NO1 or a variant thereof which composition triggers the production of antibodies in the subject or had no previous exposure to SARS-CoV-2 or any component of it, comprising the step determining in a sample the presence or absence of an IgA class antibody to SEQ ID NO1, wherein the sample comprises a set of representative antibodies from the subject.
  • the present invention also relates to method for determining whether a subject produces antibodies as a result of administration of a vaccine for distinguishing whether a subject produces antibodies as a result of administration of a vaccine or as a result of a previous corona virus infection, comprising the step detecting in a sample comprising antibodies from said subject the absence or presence of an antibody to SEQ ID NO1 and the absence or presence of an antibody to SEQ DI NO2.
  • SARS-CoV-2 is a coronavirus which has four major structural proteins, specifically the spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins.
  • the N protein holds the RNA genome, while the other three structural proteins are components of the viral envelope.
  • the S protein is responsible for allowing the virus to attach and fuse to the membrane of a host cell. It comprises an S1 domain which mediates the attachment and an S2 domain which mediates the fusion of the viral cellular membrane with the host cell.
  • the S1 domain comprises the receptor binding domain (RBD), the binding site to the receptor angiotensin converting enzyme 2 (ACE2) on human host cells.
  • RBD is the major binding site of neutralizing antibodies which block the interaction between the virus and its host cells, thus conferring immunity.
  • SARS-CoV-1 and SARS-CoV-2 which are associated with a high mortality and severe illness
  • coronaviruses 229E, NL63, OC43 and HKU1 which are associated with a mild and passing illness
  • coronaviruses 229E, NL63, OC43 and HKU1 are frequently associated with common cold, in particular among children.
  • immunized subjects In view of the massive impact of SARS-CoV-2 on economy and healthcare systems, there is considerable interest in being able to distinguish non-immunized healthy, immunized healthy and infected subjects.
  • immunized subjects vaccinated or previously infected, may be less contagious than non-immunized subjects. They may be able to return to regular work sooner than non-immunized patients.
  • Vaccinated patients may be interested in being able to or may in fact be required to demonstrate their immunization status, more specifically the fact that they have been vaccinated. This may be required if the vaccination is insufficiently documented or was performed in a country with sub-standard health standards or the quality of the vaccine used is questioned. In addition, mistakes, for example the use of physiological salt buffers rather than the vaccine, have been reported. Not in the least, falsified documents confirming vaccination are circulating.
  • confirmation that the vaccination has been effective and has been carried out may be required before the person is allowed to return to work, for example in an office shared with others, or to attend social or public events such as concerts or even immigrate from countries with a high number of active SARS-CoV-2 cases.
  • IgG class antibodies Most commercially available methods for determining the immune states relate to the detection of IgG class antibodies, because it is generally the most persistent reaction after an immunization to a viral or bacterial pathogen and may last for months or even years.
  • IgG class antibodies may be detectable only after approximately 20 days ( Meyer, Drosten & Müller, Virus Research 194 (2014); 175-186 ). This means that serological confirmation of a successful vaccination is available only late after the vaccination. Vaccinated persons may be excluded from coming to work or joining social or public events meanwhile.
  • WO2005118813 discloses the detection of IgA class antibodies to SARS-CoV-1 in fecal and mucosal samples from mice following the administration of a vaccine based on a spike protein. There is no indication that IgA could be detected in serum, let alone in humans, let alone more rapidly than IgG after a vaccination or in fact early after the vaccination at all.
  • the problem underlying the present invention is to provide a method for such a distinction, in particular where a subject may have been vaccinated by administration of a composition comprising the S1 protein from SARS-CoV-2 or not.
  • Another problem underlying the present invention is to provide a method for distinguishing non-immunized healthy, immunized health and infected subjects.
  • Another problem underlying the present invention is to provide one of the aforementioned methods, whereas an initial result may be obtained as soon as possible, in particular before the IgG class antibody response is detectable.
  • the problem is solved by a method for determining the immune status of a subject, more specifically whether the subject has been vaccinated with a composition comprising SEQ ID NO1 or a variant thereof which composition triggers the production of antibodies in the subject or had no previous exposure to SARS-CoV-2 or any component of it, comprising the step determining in a sample the presence or absence of an IgA class antibody to SEQ ID NO1, wherein the sample comprises a set of representative antibodies from the subject.
  • the problem underlying the present invention is solved by a method for determining whether a subject produces antibodies as a result of administration of a vaccine, comprising the step detecting in a sample comprising antibodies from said subject
  • the problem underlying the present invention is solved by a method for distinguishing whether a subject produces antibodies as a result of administration of a vaccine or as a result of a previous corona virus infection, preferably SARS-CoV-2 infection comprising the step detecting in a sample comprising antibodies from said subject
  • the antibody to SEQ ID NO2 is an antibody to SEQ ID NO3.
  • the antibody to SEQ ID NO1 is an IgA, IgG or IgM class antibody, preferably IgG or IgM, more preferably IgG.
  • the antibody to SEQ ID NO2 is an IgA, IgG or IgM class antibody, preferably IgM or IgG, more preferably IgG.
  • any antibody is detected using a method selected from the group comprising immunodiffusion techniques, immunoelectrophoretic techniques, light scattering immunoassays, agglutination techniques, labeled immunoassays such as those from the group comprising radiolabeled immunoassays, enzyme immunoassays such as colorimetric assays, chemiluminscence immunoassays and immunofluorescence techniques.
  • the presence or absence of the antibody in step a) is monitored over at least one, preferably two, more preferably four weeks.
  • the problem underlying the present invention is solved by use of a first polypeptide comprising SEQ ID NO1 or a variant thereof and a second polypeptide comprising SEQ ID NO2 or a variant thereof for determining whether a subject produces antibodies as a result of administration of a vaccine.
  • the problem underlying the present invention is solved by a use of a first polypeptide comprising SEQ ID NO1 or a variant thereof and a second polypeptide comprising SEQ ID NO2 or a variant thereof for distinguishing whether a subject produces antibodies as a result of administration of a vaccine or as a result of a previous corona virus infection, preferably SARS-CoV-2 infection.
  • the first and the second polypeptide are coated on a diagnostically useful solid carrier.
  • the carrier is selected from the group comprising a bead, a test strip, a microtiter plate, a microarray, a blot, preferably from the group comprising western blot, line blot and dot blot, a glass surface, a slide, a biochip and a membrane, and is most preferably a microtiter plate or a line blot.
  • the method is for determining the efficacy of a vaccine candidate comprising a polypeptide comprising SEQ ID NO1 or a variant thereof.
  • the vaccine does not comprise SEQ ID NO2 or an immunogenic variant thereof, preferably an immunogenic variant.
  • SEQ ID NO1 S1
  • the sample is a blood sample, preferably from the group comprising serum, plasma and whole blood.
  • a saliva sample may also be used.
  • an IgA class antibody, methods, uses and reagents including kits according to the invention are used to increase the sensitivity of a method for detecting the immunization status of a subject, more specifically whether the subject has been vaccinated with a composition comprising SEQ ID NO1 or a method for distinguishing whether a subject produces antibodies as a result of administration of a vaccine or as a result of a previous SARS-CoV-2 infection comprising the step detecting in a sample comprising antibodies from said subject.
  • the method or use or reagent is used no longer than 28, 21, 14, 12, 10, 8, 7, 6, 5 or 4 days after the first administration of the vaccine.
  • the present invention centers around determining the immune status of a subject, more specifically whether the subject has been infected previously, but is now healthy, has been vaccinated or had no previous exposure to SARS-CoV-2 or any component of it. It is based on the inventors' surprising finding that following a vaccination with a vaccine comprising SEQ ID NO1 or a fragment thereof, IgA class antibodies to SEQ ID NO1 may be detectable before IgG class antibodies to SEQ ID NO1 are. In other words, detecting IgA class antibodies increases the chance to confirm a successful vaccination earlier than using a conventional assay based on the detection IgG class antibodies.
  • IgA dominates the early neutralizing antibody response to SARS-CoV-2, Science Translational Medicine, 2021 Vol. 13, Issue 577 ).
  • IgA antibodies are generally not considered diagnostically relevant by the person skilled in the art except for specific cases, such as in cases of infections by entero viruses ( Gressner/Arndt, Lexikon der Medizinischen Labordiagnostik, 2. Auflage, Springer, 2013, page 1387 ), but if they appear, their titer will typically be lower than IgM and IgG class antibodies, and they may appear later.
  • IgA class antibodies do not appear earlier than IgG after infections ( Meyer, Drosten & Müller, Virus Research 194 (2014); 175-186 ).
  • SARS-CoV-2 a high sensitivity of diagnostic assays detecting IgA class antibodies to SEQ ID NO1 has been reported, but IgA and IgG class antibodies first appeared at the same time, in a sample taken after approximately 12 days.
  • the term "SARS-CoV-2", as used herein, refers to a virus characterized by the genome deposited on GenBank under accession code MN908947 or SEQ ID NO: 13, preferably as shown in SEQ ID NO: 13, and derivatives thereof having at least 80, preferably 85, preferably 88, preferably 90, preferably 91, preferably 92, preferably 93, preferably 94, preferably 95, preferably 96, preferably 97, preferably 98, preferably 99, preferably 99.5, preferably 99.8, preferably 99.9 or 99.99 percent sequence identity over the entire genome nucleotide sequence. More preferably, mutants such as those from the group comprising the U.K. variant B.1.1.7, the South African variant B.1.351, the Brazilian variant P.1 and the Mink Variant from Denmark are included.
  • the SARS-CoV-2 infection relating to a vaccination may be associated with the U.K. variant B.1.1.7 characterized by a spike protein having, with reference to SEQ ID NO1, one or more mutations, preferably all mutations from the group comprising deletion(s) in His 54 and/or Val55, Gln486Tyr, Ala555Asp, Asp599Gly and Pro666His.
  • a variant of SEQ ID NO1 having one or more mutations preferably all from the group comprising deletion(s) in His 54 and/or Val55, Gln486Tyr, Ala555Asp, Asp599Gly and Pro666His, is used for reagents, methods and uses according to the present invention.
  • a variant of SEQ ID NO1 comprising all these mutations is represented by SEQ ID NO: 51.
  • the SARS-CoV-2 infection relating to a vaccination may be associated with the South African variant B.1.351 characterized by a spike protein having, with reference to SEQ ID NO1, one or more mutations, preferably all mutations from the group comprising Lys402Gln, Glu469Lys, Gln486Tyr and Asp599Gly.
  • a variant of SEQ ID NO1 having one or more mutations, preferably all from the group comprising Lys402Gln, Glu469Lys, Gln486Tyr and Asp599Gly is used for reagents, methods and uses according to the present invention.
  • a variant of SEQ ID NO1 comprising all these mutations is represented by SEQ ID NO: 52.
  • the SARS-CoV-2 infection relating to a vaccination may be associated with the Brazilian variant P.1 characterized by a spike protein having, with reference to SEQ ID NO1, one or more mutations, preferably all mutations from the group comprising Glu469Lys and Gln486Tyr.
  • a variant of SEQ ID NO1 having one or more mutations, preferably all from the group comprising Glu469Lys and Gln486Tyr is used for reagents, methods and uses according to the present invention.
  • a variant of SEQ ID NO1 comprising all these mutations is represented by SEQ ID NO: 53.
  • the SARS-CoV-2 infection relating to a vaccination may be associated with the Mink Variant from Denmark characterized by a spike protein having, with reference to SEQ ID NO1, one or more mutations, preferably all mutations from the group comprising deletion(s) in His 54 and/or Val55, Asp599Gly and Tyr438Phe.
  • a variant of SEQ ID NO1 having one or more mutations, preferably all from the group comprising deletion(s) in His 54 and/or Val55, Asp599Gly and Tyr438Phe is used for reagents, methods and uses according to the present invention.
  • a variant of SEQ ID NO1 comprising all these mutations is represented by SEQ ID NO: 54.
  • the subject is from a species that may be infected by SARS-CoV-2 and may develop an immune response against it.
  • the subject is a mammal or a bird, more preferably a mammal, more preferably a mammal from the group comprising goat, rabbit, horse, mouse, rat, donkey, bat, camel, primate and human, most preferably human.
  • the sample is from such a subject. It may be obtained from a subject who has been or claims to have been vaccinated using a commercially vaccine based on SEQ ID NO1 or a variant thereof such as COVID-19 Moderna®. It may be obtained from a subject from an anonymous cohort of subjects for the purpose of research, for example to study the proportion of vaccinated subjects in a population or in a subpopulation, for example a group which has been vaccinated. It may be obtained as part of a trial using animals to check the immunogenicity or efficacy of a vaccine or it may be obtained from a human subject in a clinical trial, where the titers of antibodies are preferably monitored. In a preferred embodiment, it comprises a set of representative antibodies from the subject.
  • the sample comprises a fraction of the sample enriched with regard to antibodies, preferably with regard to a class of antibodies, for example IgG, IgA and IgM.
  • the sample is a blood sample, preferably selected from the group comprising whole blood, serum or plasma.
  • the subject may be a laboratory animal.
  • the presence or absence of an antibody to SEQ ID NO1 is determined, preferably an antibody from the group of classes comprising IgG, IgA and IgM.
  • the class of the antibody to SEQ ID NO1 may be IgG.
  • the class of the antibody to SEQ ID NO1 may be IgM.
  • the class of the antibody to SEQ ID NO1 may be IgA.
  • the presence or absence of an antibody to SEQ ID NO2 is determined, preferably an antibody from the group of classes comprising IgG, IgA and IgM.
  • the class of the antibody to SEQ ID NO2 may be IgG.
  • the class of the antibody to SEQ ID NO2 may be IgM.
  • the class of the antibody to SEQ ID NO2 may be IgA.
  • the presence or absence of an antibody to SEQ ID NO3 is determined, preferably an antibody from the group of classes comprising IgG, IgA and IgM.
  • the class of the antibody to SEQ ID NO3 may be IgG.
  • the class of the antibody to SEQ ID NO3 may be IgM.
  • the class of the antibody to SEQ ID NO3 may be IgA.
  • antibodies of the same class against SEQ ID NO1 and SEQ ID NO2 are detected, preferably IgA, IgM or IgG, more preferably IgG.
  • the inventive method is carried out in two steps: in a first step, IgG class antibodies to SEQ ID NO1 are detected and if the result is negative, IgA class antibodies, optionally in addition IgM class antibodies, to SEQ ID NO1 are detected to enhance the overall sensitivity.
  • the products, methods and uses of the present invention are configured such that the presence or absence of an antibody to SEQ ID NO: 1 can be detected, without determining whether the antibody detected belongs to a certain immunoglobulin class. This is often referred to as detecting the "total antibodies" to one or more antigens such as SEQ ID NO: 1. Detecting total antibodies, including at least IgA and IgG and preferably in addition IgM, increases the sensitivity of the assay, since IgA class antibodies are detected as part of the total antibodies to SEQ ID NO: 1.
  • the time point of the vaccination may be unknown, in particular if a sample from an anonymous subject is examined or if a person with memory loss, a symptom of many neurological diseases or associated with age, is checked.
  • the range of possible samples in particular in a large cohort, may comprise samples from recently vaccinated persons in which antibodies can be detected only if the presence of absence of IgA class antibodies to SEQ ID NO1 is detected.
  • the assay according to the present invention will increase the overall sensitivity.
  • an antibody to SEQ ID NO: 1 can be distinguished from an antibody to another SARS-CoV-2 antigen such as N protein (SEQ ID NO: 30) or S2 domain (SEQ ID NO: 32), more preferably because other SARS-CoV-2 antigens are absent or spatially separated or an antibody to such another SARS-CoV-2 produces a signal which can be distinguished from a signal produced by an antibody to SEQ ID NO: 1.
  • SARS-CoV-2 antigen such as N protein (SEQ ID NO: 30) or S2 domain (SEQ ID NO: 32
  • the products, methods and uses of the present invention are configured such that presence or absence of an antibody to SEQ ID NO: 1 can be detected, without determining whether the antibody detected binds to SEQ ID NO: 1 or to another SARS-CoV-2 antigen such as N protein or S2 protein.
  • This may be accomplished by using a mixture of antigens comprising SEQ ID NO: 1 or a variant thereof in combination with N protein (SEQ ID NO: 30) or a variant thereof or S2 domain (SEQ ID NO: 32) or a variant thereof.
  • the whole spike protein comprising S1 and S2 domain (SEQ ID NO: 32) may be used, optionally in combination with N protein (SEQ ID NO: 30). Again, the sensitivity of such an assay is increased since IgA class antibodies are detected as part of the total antibodies to SEQ ID NO: 1.
  • the products, methods and uses of the present invention are configured such that presence or absence of an antibody to SEQ ID NO: 1 can be detected, without determining whether the antibody detected belongs to a certain immunoglobulin class. This procedure is often referred to as detecting the "total antibodies" to one or more antigens such as SEQ ID NO: 1.
  • an antibody to SEQ ID NO1 is present in the sample, this indicates that the subject has been vaccinated, suffers from a SARS-CoV-2 infection or suffered from a SARS-CoV-2 infection.
  • detection of an IgA class antibody to SEQ ID NO1 indicates a recent infection or recent vaccination.
  • additional parameters such as whether SARS-CoV-2 infection symptoms or additional antibodies are detectable or whether or not the subject has likely been exposed to infected patients recently may be considered to distinguish between an infection and a vaccination.
  • an IgA class antibody indicates an increased likelihood that the vaccination was effective, especially if the patient resided in an area with a low incidence of SARS-CoV-2 infections.
  • Personal behavior such as quarantine or strict social distancing may also be considered.
  • an antibody to SEQ ID NO1 is present in the sample and optionally an antibody to SEQ DI NO2 is absent, this indicates an increased likelihood that the subject has been successfully vaccinated with a vaccine comprising S1 protein from SARS-CoV-2 or a variant thereof, which preferably does not comprise a polypeptide comprising SEQ ID NO2 or a variant thereof.
  • an antibody to SEQ ID NO2 is present in the sample and an antibody to SEQ DI NO1 is absent, this indicates an increased likelihood that the subject has been successfully vaccinated with a vaccine comprising nucleocapsid protein from SARS-CoV-2 or a variant thereof, which may comprise a polypeptide comprising SEQ ID NO2, preferably SEQ ID NO3 or a variant thereof.
  • the level of antibodies to SEQ ID NO1 increases, while the level of antibodies to SEQ ID NO2 does not increase, this indicates an increased likelihood that the subject has been successfully vaccinated with a vaccine comprising SEQ ID NO1 or a variant thereof rather than having been exposed to full SARS-CoV-2, for example by way of an infection.
  • both an antibody to SEQ ID NO1 and an antibody to SEQ ID NO2 are detectable or their levels increase, this suggests that the patient is or was infected with SARS-CoV-2. If the patient has symptoms and/or an IgM and/or IgA class antibodies can be detected or if the levels of IgM and/or IgA and/or IgG class antibodies are increasing, this suggests an active infection. The absence of symptoms and/or IgM and/or IgA class antibodies suggests a past infection. A PCR-based diagnostic assay for SARS-CoV-2 may be run in addition, in particular if a very early stage of the infection is suspected.
  • the presence or absence of symptoms typical for SARS-CoV and SARS-CoV-2 are taken into account to distinguish whether the subject suffers or has suffered from SARS or SARS-CoV2.
  • the presence or absence of an antibody to SEQ ID NO1 is detected, preferably monitored for at least 1, 2, 3, 4, 6, 8, 10, 12 or 16 weeks.
  • the presence of an antibody to SEQ ID NO2, preferably SEQ ID NO3 may be determined only if an antibody to SEQ ID NO1 is detected.
  • Antibodies to SEQ ID NO1 may be detectable before antibodies to SEQ ID NO2 are.
  • the presence of antibodies to SEQ ID NO2 is monitored for at least 1, 2, 3 or 4 weeks after a negative result or determined again at least one more later time point to increase the reliability of the result. It has to be borne in mind that IgA and IgM class antibodies emerge before IgG class antibodies do.
  • a vaccine has been administrated to the subject, preferably at least 1, 2, 3, 4, 5, 6, 7, 10, 14 days, 3, 4, 6, 8 or 10 weeks prior to the detection of antibodies according to the present invention.
  • an IgA class antibody to SEQ ID NO1 can be detected first depends on a range of parameters, for example the nature and quantity of the vaccine administered, the immune system of the patient etc.
  • an IgA class antibody can generally be detected before an IgG class antibody to SEQ ID NO1.
  • the efficacy of a vaccine to be developed or a finalized vaccine is assessed by the level of antibody or antibodies detected, for example IgA, IgM or IgG class antibodies, preferably IgG class.
  • a neutralization test may be carried out in addition to determine whether the antibodies produced are neutralizing antibodies (for example the Neutralisa assay by EUROIMMUNtechnik GmbH, EI 2606-9601-4). If a vaccine or candidate vaccine comprising SEQ ID NO1 or a variant thereof has been administrated and antibodies to SEQ ID NO1 are detectable, but not to SEQ ID NO2, then the vaccine or vaccine candidate is capable of immunizing the subject, more preferably trigger an immune response with antibodies reactive to SARS-CoV-2. If antibodies to SEQ ID NO1 are not detectable after a period of time sufficient to allow for the production of such antibodies, then the vaccine or candidate vaccine is ineffective.
  • the vaccine is a composition comprising SEQ ID NO1 or a variant thereof which composition triggers the production of antibodies in the subject, preferably to SEQ ID NO1, only, i.e. not to other SARS-CoV-2 proteins, in particular SEQ ID NO2 or SEQ ID NO3 or variants thereof, preferably immunogenic variants.
  • the composition may comprise an adjuvans and a physiologically compatible buffer such as PBS.
  • the vaccine does not comprise SEQ ID NO2 or SEQ ID NO3 or a variant thereof at a level that would be able to trigger the production of antibodies to SEQ ID NO2.
  • a vaccination may be recognized preferably only after two or three or more weeks, after a detectable level of antibodies, initially IgA or IgM class antibodies, followed by IgG class antibodies, is produced by the subject.
  • the method or use according to the present invention comprises the step providing a polypeptide comprising SEQ ID NO 1 and a variant thereof and optionally a polypeptide comprising SEQ ID NO2, preferably SEQ ID NO3 and a variant thereof, both polypeptides preferably coated on a diagnostically useful carrier or separate diagnostically useful carriers, and a sample from a subject.
  • the carrier or each carrier may then be contacted with the sample under conditions allowing for binding of any antibodies to SEQ ID NO1, SEQ ID NO2 or SEQ ID NO3.
  • the sample may then be removed and the carrier with may be washed to remove any remaining sample.
  • a secondary antibody or similar reagent or means binding to the antibody and carrying a detectable label may then be contacted with the carrier under conditions allowing formation of a complex between any bound antibody and the secondary antibody.
  • the carrier may be washed then to remove non-bound secondary antibody. Finally, the presence or absence of the antibody is detected by checking whether the secondary antibody may be detected.
  • the secondary antibody is an immunoglobulin (Ig), preferably IgG raised in a non-human species, wherein said secondary antibody specifically binds immunoglobulins of one or more specific Ig classes or fragments thereof (e.g. a constant domain of a particular Ig class) of a selected species, preferably human.
  • Ig immunoglobulin
  • An example is a polyclonal antibody raised in goat that specifically recognizes human IgA (i.e., a polyclonal goat antihuman IgA antibody).
  • the secondary antibody is a monoclonal antibody that specifically binds immunoglobulins of one or more specific Ig classes or fragments thereof (e.g.
  • a constant domain of a particular Ig class) of a species preferably human IgA.
  • Means and methods for producing (mono- or polyclonal) antibodies capable of specific binding of one or more selected target antigens are well known in the art and many are commercially available.
  • the secondary antibody may be chosen to specifically bind to only one, only two, or all three classes of Ig antibodies, i.e. IgA and IgG; or IgA and IgG.
  • a mixture of several different secondary antibodies may be used, wherein the different secondary antibodies either bind to the same one or different Ig classes (e.g., a mixture of different antibodies (e.g., polyclonal antibodies) all binding to IgA), or to, e.g. IgA and IgG; or IgA and IgM or wherein the different secondary antibodies bind to different individual target structures (e.g. one kind of secondary antibody specifically binding to IgA, and another specifically binding to IgG).
  • second antibody in its broadest sense is to be understood to refer to any kind of "binding moiety", preferably binding protein, capable of specific binding to an IgA, IgG and/or IgM class antibody or a fragment thereof such as a constant domain of a particular Ig class of a selected species, preferably human.
  • binding moieties include antibodies, for example antibodies immunologically or genetically derived from any species, for example human, chicken, camel, llama, lamprey, shark, goat, rodent, cow, dog, rabbit, etc., antibody fragments, domains or parts thereof, for example Fab, Fab', F(ab') 2 , scFab, Fv, scFv, VH, VHH, VL, VLRs, and the like, diabodies, monoclonal antibodies (mAbs), polyclonal antibodies (pAbs), mAbdAbs, phage display-derived binders, affibodies, heteroconjugate antibodies, bispecific antibodies, evibodies, lipocalins, anticalins, affibodies, avimers, maxibodies, heat shock proteins such as GroEL and GroES, trans-bodies, DARPins, aptamers, C-type lectin domains such as tetranectins; human
  • the antibody to SEQ ID NO: 1 is detected using a labeled secondary antibody, preferably a labeled secondary antibody binding to IgA, IgG and/or IgM class antibodies.
  • the term "labeled", with regard to the secondary antibody, is intended to embrace such embodiments wherein the secondary antibody is labelled by coupling, preferably physically linking, a detectable substance, such as a radioactive agent or another molecule providing a detectable signal, such as, without intended to being limiting, a fluorophore, such as a small organic chemical fluorophore such as FITC or fluorescent protein such as GFP, or an enzymatically active label, i.e. an enzyme, such as alkaline phosphatase, whose presence can be assessed and optionally be quantified based on its reactivity with, and/or conversion of, a substrate substance.
  • a detectable substance such as a radioactive agent or another molecule providing a detectable signal
  • a fluorophore such as a small organic chemical fluorophore such as FITC or fluorescent protein such as GFP
  • an enzymatically active label i.e. an enzyme, such as alkaline phosphatase, whose
  • the antibody preferably IgA, IgG or IgM class antibody
  • the diagnostically useful carrier is a line blot ( Raoult, D., and Dasch, G. A. (1989), The line blot: an immunoassay for monoclonal and other antibodies. Its application to the serotyping of gram-negative bacteria. J. Immunol. Methods, 125 (1-2), 57-65 ; WO2013041540 ).
  • the term "line blot”, as used herein refers to a test strip, more preferably membrane-based, that has been coated with one or more means for specifically capturing an antibody, preferably each of them is a polypeptide. If two or more means are used, they are preferably spatially separated on the carrier.
  • the width of the bands is at least 30, more preferably 40, 50, 60, 70 or 80 % the width of the test strip.
  • the line blot may comprise one or more control bands for confirming that it has been contacted with sample sufficiently long and under adequate conditions, in particular in the presence of human serum, or with a secondary antibody, respectively.
  • the diagnostically useful carrier is a bead.
  • Various beads for numerous applications are commercially available, mainly based on carbohydrate, for example sepharose or agarose, or plastic. They contain active or activatable chemical groups such as a carboxyl or ester group, which can be utilized for the immobilization of a means for specifically capturing an antibody.
  • the beads are beads having an average diameter of from 0.1 ⁇ m to 10 ⁇ m, from 0.5 ⁇ m to 8 ⁇ m, from 0.75 ⁇ m to 7 ⁇ m or from 1 ⁇ m to 6 ⁇ m.
  • the beads can be coated with the means for specifically capturing an antibody directly or via affinity ligands, for example biotin or glutathione and streptavidin and GST, respectively.
  • the bead may be coated with biotin or glutathione and the antigen may be fused with streptavidin or glutathione-S-transferase or a variant thereof, respectively.
  • the bead is provided in the form of an aqueous suspension having a bead content of from 10 to 90%, preferably from 20 to 80%, preferably from 30 to 70%, more preferably from 40 to 60% (w/w).
  • the bead is coated with a first detectable marker, for example a fluorescent dye.
  • the beads are paramagnetic beads, which can be easily concentrated on a surface with the aid of a magnet.
  • commercial paramagnetic beads usually contain a paramagnetic mineral, for example iron oxide.
  • a multiplicity of suitable paramagnetic beads is commercially available.
  • a bead may be labeled with a detectable label.
  • the carrier is a microtiter plate, preferably comprising at least eight wells that may be used for ELISA. Two or more microtiter plates may be used. At least one of the wells is coated with the polypeptide comprising SEQ ID NO1 or a variant thereof, and optionally at least one other well is coated with the polypeptide comprising SEQ ID NO2 or a variant thereof. At least 3, preferably 4, more preferably 5 calibrators are provided that comprise an antibody to an antigen, preferably both antigens from the group comprising SEQ ID NO1 and SEQ ID NO2 or a variant thereof, at defined concentrations and may be used to set up a calibration curve for semi-quantitative analysis.
  • the calibrators may be processed and developed in parallel to the samples.
  • a secondary antibody comprising a detectable label such as an enzymatically active label may be provided, for example a label having horse radish peroxidase activity or alkaline phosphatase activity or an enzyme capable of chemiluminescence.
  • the carrier is a microarray.
  • microarray refers to a chip spotted with a variety of spatially separate antigens, preferably at least 20, preferably 30, 40, 50, 80 or 100. They include SEQ ID NO1 and optionally SEQ ID NO2 or a variant thereof.
  • the polypeptide preferably comprising SEQ ID NO1, may be provided in any form and at any degree of purification, from tissues, fluids or cells comprising said polypeptide in an endogenous form, more preferably cells overexpressing the polypeptide, crude or enriched lysates of such cells, to purified and/or isolated polypeptide which may be essentially pure.
  • the polypeptide is a native polypeptide, wherein the term "native polypeptide", as used herein, refers to a folded polypeptide, more preferably to a folded polypeptide purified from cells, more preferably from prokaryotic or eukaryotic, preferably mammalian cells. A glycosylated form of the polypeptide may be used.
  • the polypeptide may be a recombinant protein, wherein the term "recombinant”, as used herein, refers to a polypeptide produced using genetic engineering approaches at any stage of the production process, for example by fusing a nucleic acid encoding the polypeptide to a strong promoter for overexpression in cells or tissues or by engineering the sequence of the polypeptide itself.
  • the person skilled in the art is familiar with methods for engineering nucleic acids and polypeptides encoded (for example, described in Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989), Molecular Cloning, CSH or in Brown T. A.
  • polypeptide is an isolated polypeptide, wherein the term "isolated” means that the polypeptide has been enriched compared to its state upon production using a biotechnological or synthetic approach and is preferably pure, i.e.
  • polypeptide in the respective liquid consists of said polypeptide as judged by SDS polyacrylamide gel electrophoresis followed by Coomassie blue staining and visual inspection.
  • any polypeptide on a carrier used as a means to capture an antibody is pure.
  • kits Such a kit is a container that comprises specific reagents required to practice the inventive method, in particular the diagnostically useful carrier according to the present invention, optionally in addition to one or more solutions or reagents required to practice the inventive method, preferably selected from or all from the group comprising sample dilution buffer, washing buffer and buffer comprising a means or reagent for detecting any specifically captured antibody, such as a secondary antibody which may comprise a detectable label and optionally a means for detecting the latter. Furthermore, it may comprise instructions detailing how to use the kit.
  • the kit may comprise the diagnostically useful carrier for contacting the inventive polypeptide with a sample from a subject, preferably selected from the group comprising a microtiter plate, two or more beads and a line blot.
  • the kit may comprise one or two positive controls, for example a recombinant or polyclonal antibody known to bind to SEQ ID NO1 and/or another antibody known to bind to SEQ ID NO2, preferably SEQ ID NO3, and a negative control, for example a protein having no detectable affinity to SEQ ID NO1 or SEQ ID NO2 such as bovine serum albumin.
  • the positive control may be a diluted sample from a patient who had been exposed to SARS-CoV-2.
  • a negative control may be a diluted sample from a healthy blood donor without antibodies to SARS-CoV-2.
  • Another positive sample representing a successfully vaccinated subject may be a sample from such a subject or a solution comprising an antibody to SEQ ID NO1 or SEQ ID NO2, but not both, preferably to SEQ ID NO1 only.
  • a kit may comprise one or more standard solutions, also referred to as calibrators, comprising one or more antibodies binding to SEQ ID NO1, and may comprise one or more standard solutions, also referred to as calibrator, comprising one or more antibodies binding to SEQ ID NO2, wherein the absolute or relative concentration of the antibody in each standard solution is preferably known. The concentration in the standard solutions may differ such that a concentration range is covered for a calibration curve.
  • the relative concentration of the respective antibody in two standard solutions may be 1:2, 1:5, 1:10, 1:20, 1:50 or 1:100 or more.
  • the antibody has a constant region or variant thereof or binding affinity to secondary antibodies like the antibody to be detected and/or any secondary antibody used for the detection binds to said antibody and the antibody to be detected.
  • the antibody may be a monoclonal antibody, preferably a hybrid comprising a human IgA, IgM or IgG, preferably IgG constant region or a variant thereof binding to secondary antibodies binding to human IgA, IgM or IgG, preferably IgG antibodies.
  • the kit may comprise a polypeptide comprising SEQ ID NO1 or a variant thereof, which polypeptide may optionally comprise a detectable label.
  • the kit may comprise a polypeptide comprising SEQ ID NO2 or a variant thereof, which polypeptide may optionally comprise a detectable label.
  • the kit may also comprise a washing solution.
  • the kit may comprise a suitable watertight vessel for contacting the diagnostically useful carrier with the sample in the presence of other liquids such as a reaction buffer.
  • a line blot may be provided in or in combination with an incubation tray, or a microtiter plate may be provided. Suitable vessels are described in the state of the art, for example EP3025780 or EP3025779 .
  • the kit may contain reagents for implementing a method according to the present invention, for example the method according to the 8 th aspect. Calibrators and their use, assays and reagents are described in in The Immunoassay Handbook, 3rd edition, by David Wild, Elsevier 2005, in particular Chapter 9 . Such a kit may be taken for the uses according to the present invention.
  • the antibody to be detected binds preferably specifically to SEQ ID NO1 or SEQ ID NO2, preferably SEQ ID NO3.
  • Specific binding preferably means that the binding reaction is stronger than a binding reaction characterized by a dissociation constant of 1 x 10 -5 M, more preferably 1 x 10 -7 M, more preferably 1 x 10 -8 M, more preferably 1 x 10 -9 M, more preferably 1 x 10 -10 M, more preferably 1 x 10 -11 M, more preferably 1 x 10 -12 M, as determined by surface plasmon resonance using Biacore equipment at 25 °C in PBS buffer at pH 7 or ELISA as described in the examples, preferably ELISA.
  • a medical or diagnostic device such as the diagnostically useful carrier may be prepared by expressing a recombinant variant of SEQ ID NO1 or SEQ ID NO2, preferably SEQ ID NO3 comprising an affinity tag, optionally with an artificial linker which may include a protease cleavage site, in a cell such as a eukaryotic or prokaryotic cell, contacting the expressed variant with a ligand binding specifically to the affinity tag, which ligand is immobilized on a solid phase, washing the solid phase such that non-specifically bound material from the cell is removed and eluting the expressed variant from the solid phase, preferably by adding an excess of non-immobilized ligand.
  • the variant may then be immobilized on the device.
  • the affinity tag may be removed by contacting the variant with a protease, preferably a protease recognizing the protease cleavage site, before the immobilization.
  • the affinity tag may be selected from the group of tags comprising 18A, ACP, Aldehyd, Avi, BCCP, Calmodulin, Chitin binding protein, E-Tag, ELK16, FLAG, flash, poly glutamate, poly aspartate, GST, GFP, HA, Isope, maltose binding protein, myc, nus, NE, ProtA, ProtC, Tho1d4, S-Tag, SnoopTag, SpyTag, SofTag, Streptavidin, Strep-tag II, T7 Epitope Tag, TAP, TC, Thioredoxin, Ty, V5, VSV and Xpress Tag.
  • Useful proteases include, but are not limited to TEV, Thrombin, Faktor Xa or Enteropeptidase. Suitable linkers are part of
  • the method and reagents according to the present invention may also be used for screening the potency and the usefulness of an antiviral drug, preferably in a library of drug candidates.
  • the method and reagents according to the present invention may also be used for screening whether donated blood is contaminated with coronavirus.
  • the methods and reagents according to the present invention may also be used for screening whether donated blood comprises antibodies to SARS-CoV-2 and may be used to prepare a medicament used to treat a patient suffering from SARS-CoV-2 and who may benefit from the administration of such antibodies.
  • blood comprising an antibody to SEQ ID NO1 and an antibody to SEQ ID NO2 is from a patient having been exposed to SARS-CoV-2. This may have been the results of an active infection or a vaccination using an inactivated virus or SEQ ID NO1 and SEQ ID NO2 or a variant thereof.
  • blood from a patient may be used to treat another patient suffering from a severe SARS-CoV-2 infection or to prepare a medicament for such a treatment.
  • blood from a subject having been vaccinated with a vaccine comprising SEQ ID NO1 and SEQ ID NO2 or a variant thereof, preferably an inactivated virus may be used to treat another patient suffering from a severe SARS-CoV-2 infection or to prepare a medicament for such a treatment.
  • teachings of the present invention may not only be carried out using polypeptides having the exact sequences referred to in this application explicitly, for example by function, name, sequence or accession number, or implicitly, but also using variants of such polypeptides.
  • the term "variant”, as used herein, may refer to at least one fragment of the full length sequence referred to or a polypeptide comprising said fragment, more specifically to one or more amino acid or nucleic acid sequences which are, relative to the full-length sequence, truncated at one or both termini by one or more amino acids.
  • a fragment comprises or encodes for a peptide having at least 10, 15, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500 or 600 successive amino acids of the original sequence or for a variant thereof.
  • the term "variant" relates not only to at least one fragment, but also a polypeptide or a fragment thereof comprising amino acid sequences, preferably a fragment comprising at least 25, more preferably 50, more preferably 200 successive amino acids, that are at least 40, 50, 60, 70, 75, 80, 85, 90, 92, 94, 95, 96, 97, 98 or 99 % identical to the reference amino acid sequence referred to or the fragment thereof, wherein amino acids other than those essential for the biological activity, for example the ability to bind specifically to an antibody of interest, or the fold or structure of the polypeptide are deleted or substituted and/or one or more such essential amino acids are replaced in a conservative manner and/or amino acids are added or deleted such that the biological activity of the polypeptide is at least partially preserved.
  • the state of the art comprises various methods that may be used to align two given nucleic acid or amino acid sequences and to calculate the degree of identity, see for example Arthur Lesk (2008), Introduction to bioinformatics, Oxford University Press, 2008, 3rd editi on.
  • the ClustalW software Larkin, M. A., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P. A., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., Lopez, R., Thompson, J. D., Gibson, T. J., Higgins, D. G. (2007): Clustal W and Clustal X version 2.0. Bioinformatics, 23, 2947-2948 ) is used applying default settings.
  • SARS-CoV-2-related publications on specific amino acid sequences such as Beal et al. may aid the skilled one in designing variants ( Beal, J., Mitechell, T., Wyschogrod, W., Manthey, J, and Clore, A. (2020) Highly Distinguished Amino Acid Sequences of 2019-nCoV (Wuhan Coronavirus) doi: https://doi.org/10.1101/2020.01.31.929497 , as well as publications relating to SARS-CoV, for example Hua, R., Zhou, Y., Wang, Y., Hua, Y and Tong, T.
  • variants may, in addition, comprise chemical modifications, for example labels such as isotopic labels or detectable labels or covalent modifications such as glycosylation, phosphorylation, acetylation, decarboxylation, citrullination, hydroxylation and the like.
  • labels such as isotopic labels or detectable labels
  • covalent modifications such as glycosylation, phosphorylation, acetylation, decarboxylation, citrullination, hydroxylation and the like.
  • variants may also be generated by way of fusion with other known polypeptides or variants thereof, for example artificial linkers, affinity tags, other antigens and the like.
  • SEQ ID NO4 is a fusion protein according to the present invention.
  • the variant of the polypeptide has biological activity.
  • biological activity is the ability to bind to the respective antibody such as an antibody to SEQ ID NO1 or an antibody to SEQ ID NO2, preferably SEQ ID NO3.
  • it comprises an epitope having the ability or has itself the ability to bind to the antibody to be detected, preferably from a sample from a patient suffering from SARS-CoV-2 or a patient vaccinated with a vaccine comprising SEQ ID NO1, wherein more preferably the epitope comprises a sequence comprising a stretch of at least 5, 6, 7 or 8 amino acid residues from the wildtype sequence, more specifically SEQ ID NO1 or an antibody to SEQ ID NO2. More preferably, it does not bind specifically to homologues from other coronaviruses, preferably coronaviruses other than SARS-CoV, more preferably from the group comprising NL63, 229E, OC43, HKU1.
  • the detection of the antibody or complex for the prognosis, diagnosis, methods or kit according to the present invention comprises the use of a method selected from the group comprising immunodiffusion techniques, immunoelectrophoretic techniques, light scattering immunoassays, agglutination techniques, labeled immunoassays such as those from the group comprising radiolabeled immunoassays, enzyme immunoassays such as colorimetric assays, chemiluminscence immunoassays and immunofluorescence techniques.
  • the complex preferably comprising an antibody to SEQ ID NO1, more preferably IgA class, and a polypeptide comprising SEQ ID NO1 or a variant thereof, is detected using a method selected from the group comprising immunodiffusion techniques, immunoelectrophoretic techniques, light scattering immunoassays, agglutination techniques, labeled immunoassays from the group comprising radiolabeled immunoassays, chemiluminscence immunoassays and immunofluorescence techniques.
  • a method selected from the group comprising immunodiffusion techniques, immunoelectrophoretic techniques, light scattering immunoassays, agglutination techniques, labeled immunoassays from the group comprising radiolabeled immunoassays, chemiluminscence immunoassays and immunofluorescence techniques.
  • the person skilled in the art is familiar with these methods, which are also described in the state of the art, for example in Zane, H. D. (2001): Immunology
  • the test format is an ELISA and a microtiter plate comprising wells is used as a diagnostically useful carrier.
  • the term "presence" of an antibody means that the antibody is detectable using such a method, preferably a method selected from the group comprising enzyme immunoassays, more preferably colorimetric assays or chemiluminescence immunoassays, most preferably colorimetric assays based on line blot and detection using alkaline phosphatase activity as described in the examples, even more preferably using the ELISA Kit (EI 2606-9601 A) by EUROIMMUN Medizinische Labordiagnostika AG.
  • the first and, if present, the second polypeptide or a variant thereof is immobilized on a solid phase of the carrier. It may be directly immobilized on the solid phase when contacted with the sample, but a competitive assay, a capture bridge assay, an immunometric assay, a class-specific second antibody on the solid phase, a class capture assay, direct or indirect may also be used.
  • a competitive assay, a capture bridge assay, an immunometric assay, a class-specific second antibody on the solid phase, a class capture assay, direct or indirect may also be used.
  • the principle of each of these formats is detailed in The Immunoassay Handbook, 3rd edition, edited by David Wild, Elsevier, 2005 .
  • the solid phase is a test strip or a well of a microtiter plate for ELISA or a bead, preferably a well of a microtiter plate for ELISA.
  • the first and the second polypeptide may be on the same or on different carriers.
  • a competitive assay format wherein the antibody to be detected competes with another antibody to SEQ ID NO: 1 or another ligand binding specifically to SEQ ID NO: 1.
  • the ligand binding specifically to SEQ ID NO: 1 may be selected from the group comprising an aptamer or antibody binding to SEQ ID NO: 1 and the human ACE2 receptor (SEQ ID NO: 39) or a variant thereof, the natural binding partner of the SARS-CoV-2 spike protein.
  • Such a method may comprise providing a polypeptide comprising SEQ ID NO: 1 or variant thereof and the ligand binding specifically to SEQ ID NO: 1, preferably from the group comprising an antibody, an aptamer and the ACE receptor or a variant thereof.
  • any complex comprising the antibody to be detected may then be detected by precipitating the complex, for example using an affinity ligand attached to the polypeptide comprising SEQ ID NO: 1 or to a molecule binding to the antibody to be detected such as a secondary antibody.
  • affinity ligands include glutathione and biotin.
  • a binding partner of the affinity ligand may be coated on a solid phase which binds to the affinity ligand such as GST or streptavidin, respectively.
  • Any complex precipitated may then be detected, preferably by detecting a detectable label attached to the ligand binding specifically to the polypeptide comprising SEQ ID NO: 1 or attached to the polypeptide comprising SEQ ID NO: 1, respectively.
  • a specific competitive test has been published by Tan et al. (2020) A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein protein interaction, Nature Biotechnology 38 (1073-1078 ).
  • the complex may be formed on the surface of a carrier if the ligand binding specifically to SEQ ID NO: 1 or the polypeptide comprising SEQ ID NO: 1 or a variant is coated on said surface.
  • the presence or absence of IgA, IgM and IgG class antibodies interfering with the complex formation will be detected using such a format.
  • Specific IgA class antibodies may be detected by isolating the antibodies of the Ig class of interest before, preferably from the group comprising IgA, IgM and IgG class antibodies preferably Ig, for example using Protein A or Protein G or a secondary antibody.
  • the person skilled in the art is familiar with the synthesis, selection and use of aptamers (Thiviyanathan V, Gorenstein DG.
  • a complex comprising a first and a second polypeptide comprising SEQ ID NO: 1 or a variant thereof, such as the receptor binding domain (RBD), and the antibody to be detected may be formed in a liquid phase if the antibody is present in the sample, since the antibody has two or more binding sites, each binding to a polypeptide comprising SEQ ID NO: 1.
  • Any complex comprising the antibody to be detected may then be detected by immobilizing, preferably precipitating the complex, for example using an affinity ligand attached to the first polypeptide such as glutathione or biotin and a binding partner coated on a solid phase which binds to the affinity ligand such as GST or streptavidin, respectively, which solid phase may for example be a bead.
  • any complex immobilized or precipitated may then be detected, preferably by detecting a detectable label attached to the second polypeptide.
  • the complex may be formed on the surface of a carrier if the first polypeptide comprising SEQ ID NO: 1 or a variant thereof is immobilized on said surface.
  • the first and the second polypeptide may each be labeled with two different labels which are detectable only if they are in close proximity, for example when bridged by the antibody to be detected.
  • IgA, IgM and IgG class antibodies will be detected unless the specific Ig class antibodies have been isolated before, preferably from the group comprising IgA, IgM and IgG class antibodies, preferably IgA, for example using Protein A or Protein G or a secondary antibody.
  • IgA antibodies will predominantly or only be detected in an early phase of the infection.
  • the first and the second polypeptide are spatially separate such that a signal indicating the presence of an antibody to SEQ ID NO1 and a signal indicating the presence of an antibody to SEQ ID NO2, preferably SEQ ID NO3 can be distinguished.
  • the first and the second polypeptides may be on different beads, on different wells of one or more microtiter plates or spatially separate spots on a membrane such as a blot membrane, for example Western blot, dot blot or line blot.
  • the membrane may optionally be on a microtiter plate well.
  • a vaccine comprising SEQ ID NO1 or a variant thereof is provided and preferably administered to a subject, preferably by injection.
  • the method or use comprises step c) providing the vaccine for administration to a subject or patient, preferably followed by administration to a subject or patient.
  • the antigen may be expressed in a large scale and transferred in a sterile liquid, optionally comprising an adjuvans, into a syringe for injection to the patient or another device for administration.
  • a kit comprising such a device and instructions how to use it may be manufactured or provided. The skilled person knows how to manufacture vaccines and this is described in the state of the art, for example in Wen, E. P., Ellis, R., Pujar, N. S.: Vaccine Development and Manufacturing, Wiley, 2015 .
  • the present invention comprises a range of polypeptide sequences, more specifically
  • SEQ ID NO4 cell culture supernatant was adjusted to 5 mmol/l tris chloride pH 8.0, 164 mmol/l sodium chloride, 50 mmol/l magnesium chloride, 20 mmol/l imidazole, 0,1% Triton X-100, cleared by centrifugation for 30 minutes at 17,600xg, 4°C, applied to Nickel Rapid Run (Agarose Bead Technologies, Miami, FL, USA) equilibrated with 5 mmol/l tris chloride pH 8.0, 300 mmol/l sodium chloride, 20 mmol/l imidazole and eluted by increasing the imidazole concentration to 150 mmol/l. All fractions containing SEQ ID NO3 were pooled and concentrated by ultrafiltration (VivaSpin, Sartorius, Göttingen, Germany). The final preparation was stored at -80°C until further use.
  • SEQ ID NO4 The final protein preparation of SEQ ID NO4 was treated with or without 16 mmol/l dithiotreitol and incubated at 70°C or at room temperature for 10 minutes, followed by SDS gel electrophoresis and Coomassie staining.
  • Protein identity was verified by mass spectrometry.
  • a healthy subject received on day 1 an injection into the musculus quadriceps of 12.86 ⁇ g recombinant S1 protein in physiological PBS (SEQ ID NO4).
  • Alum adjuvans (Twinrix for adults, EMRA-MED Arzneiffen GmbH) was applied according to the manufacturer's instructions.
  • the subject received an injection of another 12.86 ⁇ g S1 protein in physiological PBS buffer and 10 ⁇ l Imject alaun adjuvans in 500 ⁇ l sodium chlorid solution.
  • IgG and IgA antibodies to SARS-CoV-2 S1 and nucleoprotein were determined in serum samples from the healthy subject using serological kits (EUROIMMUN GmbH, EI 2606-9601 A, EI 2606-9601 G, EI 2606-9601-2 G and EI 2606-9601-2 M) according to the manufacturer's instructions. Briefly, the assays are based on the capture of a human antibody to an antigen such as SEQ ID NO1 using a polypeptide comprising the antigen coated on an ELISA microtiter plate. The technology is described in more detail in EP3715847 A1 .
  • secondary antibody recognizing the class of the antibody to be detected (for example IgA) with an enzymatically active label is used to detect the antibody of interest. It converts a chromogenic substrate until the reaction is stopped by addition of a stop solution, followed by measuring the absorption of the solution in each ELISA well.
  • Table 1 Antibodies to SARS-CoV-2 antigens in a subject vaccinated using S1 protein Day IgA (S1) (Cut off: ⁇ 0.8) IgG (S1) (Cut off: ⁇ 0.8) IgG (NCP) (Cut off: ⁇ 0.8) IgM (NCP) (Cut off: ⁇ 0.8) 10 0.5 0.5 - - 23 1.0 (! 0.2 - - 29 3.5 6.2 0.6 0.7
  • Antibody titers are shown in Table 3. Table 3: Antibodies to SARS-CoV-2 antigens in healthy subjects Day IgA (S1) (Cut off: ⁇ 0.8) IgG (S1) (Cut off: ⁇ 0.8) IgG (NCP) (Cut off: ⁇ 0.8) IgM (NCP) (Cut off: ⁇ 0.8) Patient 1 0,0 0,1 0,0 0,5 Patient 2 0,2 0,3 0,1 0,4 Patient 3 0,1 0,1 0,1 0,2 Patient 4 0,1 0,1 0,1 0,1 0,1
  • Antibodies to the S1 antigen comprised in the vaccine can be detected in both, but antibodies to the nucleocapsid protein only in infected patients, but not vaccinated subjects.
  • Example 2 Detection of IgA in a larger cohort of patients after vaccination
  • Example 2 In a cohort comprising 64 patients vaccinated as described in Example 1, the presence or absence of IgA antibodies to SEQ ID NO1 and IgG/IgM class antibodies to SARS-CoV-2 nucleocapsid protein was detected using the methods described in Example 2.
  • An IgA response to SEQ ID NO1 could be detected in 54/64 individuals.
  • An IgG or IgM response to nucleocapsid protein could each be detected only in one person; in both cases the person had no IgA response.
  • the specificity of the assay is also very high. According to the manual of EI 2606-9601 A, the specificity is more than 98 %, based on tests with samples from panels including a range of subject groups, including patients infected with seasonal corona viruses and more than 800 blood donors.
  • Table 1 shows a set of representative data from a patient: Pat.-ID Days after 1. vaccination Results EUROIMMUN ELISA EUROIMMUN NeutraLISA SARS-CoV-2 SARS-2 QuantiVac SARS-CoV-2 EI 2606 A EI 2606-10G EI 2606-4 various various C201201DB IgA IgG sVNT Ratio RU/ml BAU/ml OD % IH pos: ⁇ 1,1 pos: ⁇ 11 pos: ⁇ 35,2 pos: ⁇ 35 bl: 0,8- ⁇ 1,1 bl: 8- ⁇ 11 bl: 25,6- ⁇ 35,2 bl: 20- ⁇ 35 3 7 5,0 2 6 1,684 8 3 14 >7,0 82 262 0,640 65 3 23 6,0 98 314 0,607 67 3 35 > 7,0 > 120 > 384 0,008 100
  • IgG In none of the samples could IgG be detected before IgA. In 4/16 samples, IgA, but not IgG could be detected as early as 7 days after the administration of the vaccine. In another sample, IgA and IgG, the latter only just above the cut off value, could be detected. None of the samples that were taken first or in which any antibody could be first detected comprises detectable levels of IgG, but not IgA. Once IgA emerged, it could be also be detected in any samples obtained later from the same subject, confirming that the IgA immune response is persisting, but contrast to IgM, which is detectable only for few days, a short time window often missed by serological testing.
  • IgA indicates a successful vaccination earlier than IgG in a significant proportion of samples, consistent with publications by independent scientists. While it may not be possible to demonstrate the vaccination in all subjects at this early point, a significant proportion could be shown to have antibodies. Considering the considerable impact of quarantines on the economic situation of companies and personal lives of citizens, being able to detect the vaccination in at least 31.5 % of the subjects is an enormous advantage and may end unnecessary restrictions for many people and save companies considerable resources.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP21173934.7A 2020-05-15 2021-05-14 Verfahren zur bestimmung der wirksamkeit eines impfstoffs Active EP3855186B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE21173934.7T DE21173934T1 (de) 2020-05-15 2021-05-14 Verfahren zur Bestimmung der Wirksamkeit eines Impfstoffs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20175031.2A EP3734286A1 (de) 2020-05-15 2020-05-15 Verfahren zur bestimmung der wirksamkeit eines sars-cov-2 impfstoffs

Publications (4)

Publication Number Publication Date
EP3855186A2 true EP3855186A2 (de) 2021-07-28
EP3855186A3 EP3855186A3 (de) 2021-09-29
EP3855186B1 EP3855186B1 (de) 2023-12-06
EP3855186C0 EP3855186C0 (de) 2023-12-06

Family

ID=70775260

Family Applications (2)

Application Number Title Priority Date Filing Date
EP20175031.2A Withdrawn EP3734286A1 (de) 2020-05-15 2020-05-15 Verfahren zur bestimmung der wirksamkeit eines sars-cov-2 impfstoffs
EP21173934.7A Active EP3855186B1 (de) 2020-05-15 2021-05-14 Verfahren zur bestimmung der wirksamkeit eines impfstoffs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP20175031.2A Withdrawn EP3734286A1 (de) 2020-05-15 2020-05-15 Verfahren zur bestimmung der wirksamkeit eines sars-cov-2 impfstoffs

Country Status (4)

Country Link
EP (2) EP3734286A1 (de)
DE (2) DE20175031T1 (de)
PL (1) PL3855186T3 (de)
WO (1) WO2021229078A1 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114409767A (zh) * 2021-12-08 2022-04-29 广东菲鹏生物有限公司 一种鉴别新冠突变型抗原的抗体、试剂及方法
WO2022246292A1 (en) 2021-05-21 2022-11-24 PERSOWN, Inc. Electrochemical diagnostic system and methods of obtaining and using electrochemical diagnostic results
US11513097B1 (en) 2021-05-21 2022-11-29 PERSOWN, Inc. Methods of obtaining and using electrochemical diagnostic results
WO2023056143A1 (en) * 2021-09-30 2023-04-06 Siemens Healthcare Diagnostics Inc. Compositions, kits, and methods for duplex immunoassay for anti-sars-cov-2 antibodies

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112442120A (zh) * 2020-11-25 2021-03-05 苏州大学 抗严重急性呼吸系统综合征ii型冠状病毒sars-cov-2的中和抗体
IT202000030740A1 (it) 2020-12-14 2022-06-14 St Superiore Di Sanita SEQUENZA NUCLEOTIDICA ESPRIMENTE UNA PROTEINA ANCORANTE VESCICOLE EXTRACELLULARI FUSA AD ANTIGENI DI SARS-CoV-2 E RELATIVA PROTEINA DI FUSIONE PER L’USO COME VACCINO
CN112611870B (zh) * 2020-12-21 2022-09-16 杭州宝临生物科技有限公司 预测新型冠状病毒中和抗体效价的方法及其试剂盒
CN112285348B (zh) * 2020-12-29 2021-03-16 北京百普赛斯生物科技股份有限公司 新冠病毒疫苗表达抗原蛋白的电化学发光免疫检测试剂盒
CN112546213A (zh) * 2020-12-31 2021-03-26 中国医学科学院医学生物学研究所 一种制备新型冠状病毒疫苗的方法及针对其有效性的评价方法
CN113203855A (zh) * 2021-01-13 2021-08-03 广东菲鹏生物有限公司 Rbd中和抗体检全方法及产品
CA3206950A1 (en) * 2021-01-29 2022-08-04 Flowmetric Life Sciences, Inc. Detecting sars-cov-2 and other infective agents
JP6976621B1 (ja) * 2021-02-04 2021-12-08 株式会社Icst 検査器具、検査キットおよび検査方法
WO2022175842A1 (en) * 2021-02-17 2022-08-25 Eltek S.P.A. Kit and process for testing a state of immunization in a subject with respect to a pathogenic microorganism
EP4326437A4 (de) * 2021-04-21 2024-09-11 Siemens Healthcare Diagnostics Inc Zusammensetzungen, kits und verfahren für antimikrobielle serologietests unter verwendung von anti-humanem immunglobulinantikörper

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118813A2 (en) 2004-06-04 2005-12-15 Institut Pasteur Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
WO2013041540A1 (de) 2011-09-24 2013-03-28 Euroimmun Medizinische Labordiagnostika Ag Kalibrationsstreifen für einen immunoblot
EP3025779A1 (de) 2014-11-26 2016-06-01 Euroimmun Medizinische Labordiagnostika AG Inkubationswanne
EP3025780A1 (de) 2014-11-26 2016-06-01 Euroimmun Medizinische Labordiagnostika AG Inkubationswanne
EP3715847A1 (de) 2020-02-20 2020-09-30 Euroimmun Medizinische Labordiagnostika AG Verfahren und reagenzien zur diagnose von sars-cov-2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102021003012A2 (pt) 2020-02-19 2021-11-30 Univ Berlin Charite Métodos para o diagnóstico de infecção por sars-cov-2, kit e usos
CN111088283B (zh) * 2020-03-20 2020-06-23 苏州奥特铭医药科技有限公司 mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118813A2 (en) 2004-06-04 2005-12-15 Institut Pasteur Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
WO2013041540A1 (de) 2011-09-24 2013-03-28 Euroimmun Medizinische Labordiagnostika Ag Kalibrationsstreifen für einen immunoblot
EP3025779A1 (de) 2014-11-26 2016-06-01 Euroimmun Medizinische Labordiagnostika AG Inkubationswanne
EP3025780A1 (de) 2014-11-26 2016-06-01 Euroimmun Medizinische Labordiagnostika AG Inkubationswanne
EP3715847A1 (de) 2020-02-20 2020-09-30 Euroimmun Medizinische Labordiagnostika AG Verfahren und reagenzien zur diagnose von sars-cov-2

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
"GenBank", Database accession no. MN908947
"Handbook of Therapeutic Antibodies", 2007, article "Non-Antibody Scaffolds"
ARTHUR LESK: "Introduction to bioinformatics", 2008, OXFORD UNIVERSITY PRESS
BEAL, J.MITECHELL, T.WYSCHOGROD, W.MANTHEY, JCLORE, A., HIGHLY DISTINGUISHED AMINO ACID SEQUENCES OF 2019-NCOV (WUHAN CORONAVIRUS, 2020
BROWN T. A.: "Gene Cloning - an introduction", 1986, CHAPMAN & HALL
BURGESS, R. R.DEUTSCHER, M. P., GUIDE TO PROTEIN PURIFICATION, 2009
CHIU ML, ANTIBODIES (BASEL, vol. 8, no. 4, 2019, pages 55
DAHLKE, C.HEIDEPRIEM, J.KOBBE, R.SANTER, R.KOCH, T.FATHI, A.LY, M. L.SCHMIEDEL, S.SEEBERGER, P. H.LOEFFLER, F., MEDRXIV, 2020, Retrieved from the Internet <URL:https://doi.org/10.1101/2020.04.14.20059733>
DAVID WILD: "The Immunoassay Handbook", 2005, ELSEVIER
GRESSNERARNDT: "Lexikon der Medizinischen Labordiagnostik", 2013, SPRINGER, pages: 1387
HANACK KMESSERSCHMIDT KLISTEK M: "Antibodies and Selection of Monoclonal Antibodies", ADV EXP MED BIOL., vol. 917, 2016, pages 11 - 22, XP009193978, DOI: 10.1007/978-3-319-32805-8_2
HAROLD F. STILLS, THE LABORATORY RABBIT, GUINEA PIG, HAMSTER, AND OTHER RODENTS, 2012
HUA, R.ZHOU, Y.WANG, Y.HUA, YTONG, T., IDENTIFICATION OF TWO ANTIGENIC EPITOPES ON SARS-COV SPIKE PROTEIN, BBR, vol. 319, 2004, pages 929 - 935
HUST MFRENZEL ASCHIRRMANN TDUBEL S: "Selection of recombinant antibodies from antibody gene libraries", METHODS MOL BIOL., vol. 1101, 2014, pages 305 - 20
JACKSON ET AL.: "An mRNA Vaccine against SARS-CoV-2 - Preliminary Report", IN ENGL J MED, vol. 383, 2020, pages 1920 - 1931
LARKIN, M. A.BLACKSHIELDS, G.BROWN, N. P.CHENNA, R.MCGETTIGAN, P. A.MCWILLIAM, H.VALENTIN, F.WALLACE, I. M.WILM, A.LOPEZ, R.: "Clustal W and Clustal X version 2.0", BIOINFORMATICS, vol. 23, 2007, pages 2947 - 2948
LOTTSPEICHENGELS: "Bioanalytic", 2012, SPRINGER
MCLNTYRE PJOO YJCHIU CFLANAGAN KMACARTNEY K: "COVID-19 vaccines - are we there yet?", AUST PRESCR., vol. 44, no. 1, 2021, pages 19 - 25
MEYERDROSTENMULLER, VIRUS RESEARCH, vol. 194, 2014, pages 175 - 186
OKBA ET AL., EMERG INFECT DIS., vol. 26, no. 7, July 2020 (2020-07-01), pages 1478 - 1488
OKBA NMA ET AL.: "Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients", EMERG INFECT DIS., vol. 26, no. 7, July 2020 (2020-07-01), pages 1478 - 1488, XP055785067, DOI: 10.3201/eid2607.200841
POLACK ET AL.: "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine", N ENGL J MED., vol. 383, no. 27, 31 December 2020 (2020-12-31), pages 2603 - 2615
RAOULT, D.DASCH, G. A.: "The line blot: an immunoassay for monoclonal and other antibodies. Its application to the serotyping of gram-negative bacteria", J. IMMUNOL. METHODS, vol. 125, no. 1-2, 1989, pages 57 - 65, XP023653127, DOI: 10.1016/0022-1759(89)90078-1
SAMBROOK, J.FRITSCH, E. F.MANIATIS, T.: "Molecular Cloning", 1989, CSH
SIMEON R.CHEN Z., PROTEIN CELL, vol. 9, no. 1, 2018, pages 3 - 14
STERLIN ET AL.: "IgA dominates the early neutralizing antibody response to SARS-CoV-2", SCIENCE TRANSLATIONAL MEDICINE, vol. 13, no. 577, 2021
TAN ET AL.: "A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein protein interaction", NATURE BIOTECHNOLOGY, vol. 38, no. 1073-1078, 2020
THIVIYANATHAN VGORENSTEIN DG: "Aptamers and the next generation of diagnostic reagents", PROTEOMICS CLIN APPL., vol. 6, no. 11-12, 2012, pages 563 - 573, XP055152896, DOI: 10.1002/prca.201200042
WATANABE ET AL.: "Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine", BIORXIV [PREPRINT, 19 January 2021 (2021-01-19)
WEN, E. P.ELLIS, R.PUJAR, N. S.: "Vaccine Development and Manufacturing", 2015, WILEY

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022246292A1 (en) 2021-05-21 2022-11-24 PERSOWN, Inc. Electrochemical diagnostic system and methods of obtaining and using electrochemical diagnostic results
US11513097B1 (en) 2021-05-21 2022-11-29 PERSOWN, Inc. Methods of obtaining and using electrochemical diagnostic results
US11525799B1 (en) 2021-05-21 2022-12-13 PERSOWN, Inc. Electrochemical diagnostic system
WO2023056143A1 (en) * 2021-09-30 2023-04-06 Siemens Healthcare Diagnostics Inc. Compositions, kits, and methods for duplex immunoassay for anti-sars-cov-2 antibodies
CN114409767A (zh) * 2021-12-08 2022-04-29 广东菲鹏生物有限公司 一种鉴别新冠突变型抗原的抗体、试剂及方法

Also Published As

Publication number Publication date
EP3855186B1 (de) 2023-12-06
PL3855186T3 (pl) 2024-04-29
DE21173934T1 (de) 2021-09-23
EP3855186C0 (de) 2023-12-06
EP3855186A3 (de) 2021-09-29
DE20175031T1 (de) 2021-09-09
WO2021229078A1 (en) 2021-11-18
EP3734286A1 (de) 2020-11-04

Similar Documents

Publication Publication Date Title
EP3855186B1 (de) Verfahren zur bestimmung der wirksamkeit eines impfstoffs
EP3809137A1 (de) Verfahren und reagenzien zur diagnose einer sars-cov-2 infektion
US20230184766A1 (en) Compositions and methods for coronavirus detection
US11598772B2 (en) Method and products for the diagnosis of a seafood allergy
JP2006284567A (ja) ヘリコバクター・ピロリ感染の診断方法及び診断キット
CN113447658B (zh) 一种检测抗过氧化物还原酶-1-IgG抗体的试剂盒
TW201300421A (zh) 用於偵測豬繁殖及呼吸道綜合症病毒（ｐｒｒｓｖ）之試劑及方法
CN112964872B (zh) SARS-CoV-2检测试剂盒
US20230168247A1 (en) Specificity enhancing reagents for covid-19 antibody testing
WO2021209925A1 (en) Coronavirus serology assay
JP2021098746A (ja) 遺伝子組み換えトリパノソーマ・クルージｊｌ７抗原変異型およびシャーガス病を検出するためのその使用
EP3761029B1 (de) Neuartiger test zur diagnose von nematodeninfektionen
WO2010123083A1 (ja) マウス肝炎ウイルス由来ポリペプチドおよび／またはセンダイウイルス由来ポリペプチド、これらを用いたマウス肝炎ウイルス感染および／またはセンダイウイルス感染検査キット、ならびにマウス肝炎ウイルス感染および／またはセンダイウイルス感染の検出方法
JP4619580B2 (ja) 抗体捕捉法による抗体の免疫学的測定方法
WO2022253260A1 (zh) 新型冠状病毒及其突变株中和抗体的检测试剂盒
IL295754A (en) Methods and reagents for the diagnosis of sars-cov-2 infection
WO2021252722A1 (en) Sars-cov-2 polypeptides, ant-sars-cov-2 antibodies and uses thereof
WO2022133233A2 (en) Rocky mountain spotted fever detection and treatment
KR20160121673A (ko) 브루셀라병 진단용 형광면역진단키트

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KOMOROWSKI, LARS

Inventor name: STEINHAGEN, KATJA

Inventor name: STOECKER, WINFRIED

REG Reference to a national code

Ref country code: DE

Ref legal event code: R210

Ref document number: 602021007406

Country of ref document: DE

Ref country code: DE

Ref legal event code: R210

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101AFI20210825BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220329

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220725

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

INTG Intention to grant announced

Effective date: 20230929

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602021007406

Country of ref document: DE

Owner name: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG, DE

Free format text: FORMER OWNER: EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG, 23560 LUEBECK, DE

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602021007406

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20240105

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI

Effective date: 20240124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240307

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240307

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240306

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

U20 Renewal fee paid [unitary effect]

Year of fee payment: 4

Effective date: 20240516

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240406

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240602

Year of fee payment: 4

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20240502

Year of fee payment: 4

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231206

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240406

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20240502

Year of fee payment: 4

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602021007406

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: SIMMONS & SIMMONS LLP

Effective date: 20240904